Karyopharm Therapeutics Inc - Phase 3 SEAL Top-Line Results Conference Call Transcript
Good day. My name is Chad, and I will be your conference operator today. At this time, I would like to welcome everyone to Karyopharm Therapeutics Phase III SEAL study results conference call. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request.
I would now like to turn the conference over to Mr. Ian Karp, Karyopharm's Senior Vice President, Investor and Public Relations. Please go ahead.
Thanks so much, Chad, and thank you all for joining us on today's conference call to discuss the results from the Phase III SEAL study presented this morning at the Connective Tissue Oncology Society 2020 Annual Meeting. This is Ian Karp, and I'm joined today by Dr. Michael Kauffman, Chief Executive Officer; Dr. Jatin Shah, Chief Medical Officer; and Dr. Sant Chawla, Director of the Sarcoma Oncology Center in Santa Monica, California.
On the call today, Dr. Kauffman will provide some opening remarks
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |